- Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin
- Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space
- Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline
Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has announced that its recently acquired subsidiary, Adelia Therapeutics Inc., has achieved the earn-out milestones outlined for the time period in the contribution agreement between the two companies (https://ibn.fm/c6o2E). That milestone includes the successful synthesis of multiple tryptamine derivatives.
Furthermore, the synthesis of tryptamine derivatives resulted in quantities adequate enough that Adelia could initiate in vitro “Proof of Principle”; establish that an ADME/PK has been completed; and demonstrate “In Vitro” ADME “Proof of Principle” that specific synthesis modifies the…
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
